The quality standard of all products from the blood, as defined by the Council of Europe. It also relates to haematopoietic stem cells, their collection, production, storage, quality assurance and safety. The fundamental European document in the field of transfusion medicine.
F.23 Development of new system-wide, normative and programme solutions, and methods
COBISS.SI-ID: 706211The maintenance of the immune system and stem cell pool could prevent defects of immunity, prolong the life span and enable healthy aging. There have been many strategies tried to achieve this and counteract age-related deficits. One of these strategies that had not been tested on humans due to technical obstacles and disbelief of certain scientific and non-scientific bodies, is the autologous transplantation of young healthy hematopoietic/immune tissues, collected in youth, to the aged individual in need of immune reconstitution or therapeutic action due to cancer or other immune disease of old age. By enhancing the donor/recipient's immune system, in this manner, the donor/recipient's healthy life span could be increased. The objective of this presentation is to give an overview of age related immune disorders, to present the potential indications for preventive immune cellular enhancement, and to discuss how autologous stem cells could be administered in predetermined amounts in singular or serial fashion over predetermined time intervals in order to achieve the chimerism that would enhance the recipient’s immune system. This practice could result in replenishing the hematopoietic and immune system as well as in refreshing the repertoire of stem cells that are at the point of exhaustion. Besides there exist certain indices of improving cognitive functions of the aged recipient by using the same approach. Several animal studies that have confirmed the proof of principle of this concept will be reviewed.
B.03 Paper at an international scientific conference
COBISS.SI-ID: 32111321First Slovenian textbook of transfusion medicine. Contains important chapters on advanced cell therapies and stem cells.
C.02 Editorial board of a national monograph
COBISS.SI-ID: 278981120Mesenchymal stem cells (MSC) represent a major advance in clinical therapy to regenerate tissues or for cell therapy. Due to their immunosuppressive properties and multipotency, show utility in the treatment of various diseases and damaged tissues in regenerative medicine. In order to ensure appropriate quantities of MSC for clinical use, as an alternative methods to conventional cultivation of the adherent monolayer layers developed microcarriers (MC). MC represent a three-dimensional support matrix for attachment, further expansion and differentiation of MSC. The aim of our master's thesis was to optimize the culture conditions of MSC from adipose tissue (ASC) on MC for the high-yield culture of cells. We have shown that the highest number of cells can be obtained by selection of appropriate physical and chemical properties of MC, by preincubation of MC in the culture medium and by the medium refreshment regime. Cells grown on MC did not lose their proliferative potential compared with the control adherent culture. The differentiation experiments before and after the cultivation cells on MC shown that the ability of differentiation into adipocytes and chondrocytes remains the same, but osteogenic potential was slightly increased compared with control cultures.
F.21 Development of new health/diagnostic methods/procedures
COBISS.SI-ID: 3545423